Press Room


    Press Release - March 25, 2008

    Islet Cell Pioneer Appointed to Help Advance Sertolin Diabetes Therapy

    Kelowna, B.C. - Sernova Corp. ("Sernova") is pleased to announce that world class, pancreatic islet transplant expert, Dr. Shinichi Matsumoto, Director of the Baylor All Saints Islet Cell Laboratory at the Baylor Research Institute in Fort Worth Texas, has accepted an appointment to Sernova's Scientific Advisory Board (SAB). Dr. Matsumoto is a pioneer in human islet transplantation to treat diabetics. He has many notable accomplishments in the field of islet transplantation, which will assist Sernova in pursuing its clinical regulatory path going forward. His research has resulted in numerous scientific publications on islet isolation, preparation and transplantation. "With his knowledge of the intricacies of islet biology and islet transplants, Dr. Matsumoto is a key addition to our SAB and Sernova's diabetes therapy research," commented Dr. David White, Sernova's Principal Researcher. "His expertise in islets complements well that of the other SAB members who are experts in diabetes, immunology, and Sertoli cells."

    About Dr. Matsumoto Dr. Matsumoto is currently the Director of the Baylor All Saints Islet Cell Laboratory, and the Islet Cell Transplantation Laboratory at the Baylor Research Institute. Dr. Matsumoto graduated from medical school in 1988 and received his postgraduate training in 1996 from Kobe University School of Medicine in Kobe, Japan. He is board certified in surgery and gastroenterological surgery. He joined the medical staff of Kobe University Hospital in 1996. From 1997 to 2002, Matsumoto studied at islet transplant centers in Minneapolis and Seattle. Dr. Matsumoto joined Northwest Tissue Center (Seattle) in 2000, as senior research scientist in Human Islet Transplantation and consultant to the Human Islet Processing Facility. Just prior to joining Baylor he served as assistant professor at Kyoto University Hospital Transplantation Unit and as Director of the Diabetes Research Institute in Kyoto.

    About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin- dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.


    "Justin Leushner"

    Justin Leushner, President

    For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News